Tirzepatide
Revolutionary dual GLP-1R/GIPR agonist API (Tirzepatide, CAS 2023788-19-2) — setting new standards in metabolic disease treatment. Unmatched weight management and glucose control efficacy. High-purity, high-stability production with complete analytical documentation. Ideal for advanced formulation development.
Revolutionary dual GLP-1R/GIPR agonist API setting new standards in metabolic disease treatment. Unmatched efficacy in weight management and glucose control. High-purity, high-stability production with complete COA.
| CAS | 2023788-19-2 |
| Molecular Formula | C₂₂₅H₃₄₈N₆₈O₇₅ |
| Molecular Weight | 4813.45 g/mol |
| Category | GLP-1 & Incretin Metabolic Peptides |
| Purity | >=99% (HPLC) |
| Status | GMP-compliant, FDA-ready |
| Applications | Advanced obesity, type 2 diabetes, metabolic syndrome |
| CAS | 2023788-19-2 |
|---|---|
| Applications |
Related products
-
Abarelix
CAS: 183552-38-7Applications: Advanced Prostate Cancer, Hormone-dependent Tumors, Testosterone Suppression -
Liraglutide
CAS: 204656-20-2Applications: cardiovascular risk reduction, GLP-1, obesity management -
Pramlintide
CAS: 196078-30-5 -
Aviptadil
CAS: 40077-57-4Applications: Acute respiratory distress syndrome, ARDS, Lung protection, Pulmonary hypertension, VIP analog